Tumor-promoting M2 macrophages can contribute to tolerance to MAPK inhibition, and their accumulation within tumors during treatment strongly correlates with an aggressive phenotype in different melanoma models, through different mechanisms, including VEGF and TNF-alpha secretion. The gene discussed is TNF; the disease is neoplasm.